Cannabis MS drug seeks approval
September 2006
The Daily Telegraph
By Rosie Murray-West, Business Correspondent

The first medicinal product based on cannabis was filed for approval in Britain yesterday, and could be widely available in a year's time.

Sativex, based on cannabis extract, is aimed at multiple sclerosis sufferers and is intended to treat the muscle stiffness associated with the condition.

The drug has been developed by GW Pharma, which is growing 11 acres of cannabis under glass at a secret location somewhere in Britain.

Some patients already use Sativex, which is imported from Canada where it is already approved, but British approval would make it far more widely available. At present most sufferers pay around 4 a day for the drug.

A spokesman for the MS Society said a "very significant number" of Britain's 85,000 sufferers could benefit from using the drug, which at present is not available to many. "

People with MS are sourcing raw cannabis of whatever quality from goodness knows where and running goodness knows what risks," he said. "It is important that we do see properly tested, effective, cannabis-based drugs."

The drug has already been filed for approval once, but British regulators said they required more information.

Yesterday, Stephen Wright, of GW Pharma, said he was confident in the new data the company had obtained.

''We have a sizeable body of positive clinical data to support the efficacy and safety of Sativex in MS spasticity," he said. He believed that the drug would be widely available within 12 to 15 months.
http://www.telegraph.co.uk

have been in and out of this "sucker" a few times now but not calling them "suckers" anymore- last 2 months have been amazing

new all time high!!!!!!!!!!!!!!!!!

400p , I WILL SELL

once 400p/s better to put a stoploss order out at say 380 and let it ride and ride and ride whilst increasing stoploss level if and when needed

StockMarketWire.com
GW Pharmaceuticals has announced the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex (cannabidiol or CBD) for the treatment of Dravet syndrome.

In this study, Epidiolex achieved the primary endpoint of a significant reduction in convulsive seizures assessed over the entire treatment period compared with placebo (p=0.01).

Epidiolex has both Orphan Drug Designation and Fast Track Designation from the US FDA in the treatment of Dravet syndrome, a rare and debilitating type of epilepsy for which there are currently no treatments approved in the US.

thought i'ld revive this one .....

GWPH.NQ = GW Pharmaceuticals
i just thought to remind you all of this funny little stock, a brief synopsis below ....
GW Pharmaceuticals is a British biopharmaceutical company known for its multiple sclerosis treatment product nabiximols. Sativex is the first natural cannabis plant derivative to gain market approval in any country.

this used to be quoted on AIM but delisted and is now to be found on nasdaq, where it has been performing adequately

with the current interest in pharamas in general and legal cannabis incidentally, this may have some appeal to you chaps (i hold)

cheap way to invest in U S A is there one informed one please reply . BB

why any problem investing in US stocks?
i generally put them in my sipp, and thus go through that broker

Have to admit I missed this delisting from AIM.... it was shown as RNS November 2016 - DYOR. Now it trades on NASDAC, I read.... but I'm unhappy that companies can jump-ship like this . . . why are they allowed to rubbish the long-term investors who thought there was a future with them?

I was always wary of GWP, not for any inherent "medical breakthrough" issues... the plant has been about for a long time and its underlying properties are established.... The issue I had ( & Still retain), is that you can grow the plant for these effects. Sure, it may be "Illegal" but so is bath-tub gin.... yet there is very little the Authorities can do about small production.
= HOWEVER, if the law was changed and Cannabis became a "regular" drug - the Big Pharmas would blow GWP away with their Marketing Might and connections to the Public-perception, etc. all IMHO . . . and what do I know?
/
EDIT (June2018)- Yes, it was the increased load of paperwork that offends me.
+++ With Cannabis in the UK-News recently... I still wonder if this Guildford-based Co. will ever be good for UK-retail shareholders . . . you'd think so, but there is an aside-issue where some Countries / States are allowing Cannabis to be sold - in effect this removes GWP - their product is dead-in-the-water if folks can self-medicate ( even with some risk).
It is said that the tax from Legal-Cannabis would pay for the NHS! Wow" - that's a lot of Dope.

GWPO
they didn't!
shareholders were able to exchange london shares for those on nasdaq

Big Pharmas can not blow them away as GWP got patents (either secured or in pipeline I know/understand) . That does not rule out a takeover of course.
Agree with hangon that switching from AIM to NASDAQ was not very kind to small UK investors who had supported GWP all along in AIM and regardless being able to switch to NASDAQ listing , which also require more forms to fill out and more exchanges to look at and more currency movements to take into account.

confess i found few if any problems
the transfer was quick and simple and effectively handled by my broker

GWPH (nasdaq)
you guys should remember this one from when it was quoted in london
i now hold the nasdaq stock where it is steadily rising

GW Pharmaceuticals: A first-mover in cannabis-derived prescription drugs
Founded in 1998, GW Pharmaceuticals is the first-mover in developing prescription drugs derived from cannabinoids. The company made history when it launched Sativex in the U.K. in 2010. This was the world's first drug derived from the cannabis plant to receive regulatory approval in any country. Sativex is now sold in many countries, though not in the U.S., as a mouth spray for alleviating neuropathic pain and other symptoms of multiple sclerosis.

In June 2018, GW Pharmaceuticals dove into the record books again when Epidiolex became the first drug derived from a cannabis plant to get the nod from the U.S. Food and Drug Administration. The drug, which is slated to launch this fall, is approved to treat patients with two forms of epilepsy. In September, the company notched another "first" when the U.S. Drug Enforcement Administration classified Epidiolex as a Schedule V drug, which is the least restrictive prescribing category of controlled substances. The DEA had to get involved because all marijuana-derived products automatically fall into the most restrictive Schedule I classification since cannabis is not legal in the U.S. on the federal level.

While GW Pharmaceutical isn't profitable, Wall Street analysts expect it to be in five years. GW's balance sheet is hardy enough to withstand the company continuing to invest in growth while Epidiolex's sales ramp up. (Market researcher EvaluatePharma projects Epidiolex will generate sales of nearly $1 billion per year by 2022, as my colleague Keith Speights reported.) At the end of the second quarter, the company had nearly $442 million in cash and cash equivalents, which, at its current rate of cash burn -- about $142 million per year -- will last about three years

it's up 11.7% since start of the year, which is fine by me :-)

please dont remind me of this share..got stopped out just before the meteoric rise thanks to VOG!

I was in it for 10 years or more...barstards!

Made a very handy profit in the past on this one and would have kept my holding until it said goodbye to ftse and married Nasdaq which I do not trade.
With current cannabis developments I think by tomorrow I may change my mind and have a punt with them again albeit "overseas"